Skip to main content
Premium Trial:

Request an Annual Quote

RBM Nets $25M in VC Cash; Funds Will Help Finance M&A, Grow Dx Service

NEW YORK (GenomeWeb News) — Multiplexed biomarker testing lab Rules-Based Medicine has raised $25 million in a Series A round of private equity financing, the company said yesterday.
 
The Austin, Tex.-based shop said it plans to use the cash for aggressive growth in the services business, to fund development of diagnostics services and kits, to shore up its balance sheet, to repay debts, and to make acquisitions and investments in the biomarker and medical diagnostics fields.
 
In addition, RBM will use $12.5 million of the financing to pay Luminex under the terms of a lawsuit settlement disclosed earlier this week.  
 
The financing was led by Equity Group Investments, and included contributions from Cross Creek Capital and Stephens Capital Partners.
 
As part of the funding, Matt Zell, managing director of EGI, has joined RBM's board of directors.
 
 

The Scan

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.

Study Explores Animated Digital Message Approach to Communicate Genetic Test Results to Family Members

In the Journal of Genetic Counseling, the approach showed promise in participants presented with a hypothetical scenario related to a familial hereditary breast and ovarian cancer syndrome diagnosis.

Computational Tool Predicts Mammalian Messenger RNA Degradation Rates

A tool called Saluki, trained with mouse and human messenger RNA data, appears to improve mRNA half-life predictions by taking RNA and genetic features into account, a Genome Biology paper reports.

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.